Journal article · 2023 · Open access

Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study

Tomohisa Uchida, Naoki Iwamoto, Shoichi Fukui, Shimpei Morimoto, Toshiyuki Aramaki, F. Shomura, Koichiro Aratake, Katsumi Eguchi, Yukitaka Ueki, Atsushi Kawakami

Rheumatology, 62(10), 3358–3365 · Published 16 February 2023 · DOI 10.1093/rheumatology/kead079

Open PDFView at the publisherCite this paper

In brief

“Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study” is a 2023 journal article by Tomohisa Uchida and 9 co-authors, published in Rheumatology. OpenAlex counts 39 citations as of 19 November 2026, which puts it in the top 3% of works published in 2023 by citations. It is open access: the full text is free to read at Rheumatology.

Citations
39
Most cited in
2024 (15)
Field-weighted impact
6.17
References
33
Authors
10

Abstract

OBJECTIVES: The objective of this study was to compare the incidence rates (IRs) of infectious diseases, major adverse cardiovascular events (MACEs), and malignancies in RA patients treated with tofacitinib, baricitinib or a TNF inhibitor. METHODS: We retrospectively analysed the cases of 499 RA patients treated with tofacitinib (n = 192), baricitinib (n = 104), or a TNF inhibitor (n = 203). We determined the IRs of infectious diseases and the standardized incidence ratio (SIR) of malignancies and investigated factors related to infectious diseases. After adjusting the clinical characteristic imbalance by propensity score weighting, we compared the incidence of adverse events between the Janus kinase (JAK)-inhibitor and TNF-inhibitor groups. RESULTS: The observational period was 959.7 patient-years (PY), and the median observational period was 1.3 years. The IRs within the JAK-inhibitor treatment group were: serious infectious diseases other than herpes zoster (HZ), 8.36/100 PY; HZ, 13.00/100 PY. Multivariable Cox regression analyses revealed independent risk factors: the glucocorticoid dose in serious infectious diseases other than HZ, and older age in HZ. Two MACEs and 11 malignancies were identified in JAK-inhibitor-treated patients. The overall malignancy SIR was (non-significantly) higher than that of the general population (1.61/100 PY, 95% CI: 0.80, 2.88). The IR of HZ in the JAK-inhibitor-treated group was significantly higher than the TNF-inhibitor-treated group, but there were no significant differences in the IRs of other adverse events between the JAK-inhibitor-treated group and the TNF-inhibitor-treated group, or between the treatment groups of the two JAK inhibitors. CONCLUSIONS: The infectious disease IR in RA was comparable between tofacitinib and baricitinib, but the IR for HZ in these treatment groups was high compared with that in the TNF inhibitor treatment group. The malignancy rate in the JAK-inhibitor-treated group was high but not significantly different from that of the general population or that of the TNF-inhibitor-treated group.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Uchida, T., Iwamoto, N., Fukui, S., Morimoto, S., Aramaki, T., Shomura, F., Aratake, K., Eguchi, K., Ueki, Y., & Kawakami, A. (2023). Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study. Rheumatology, 62(10), 3358–3365. https://doi.org/10.1093/rheumatology/kead079

MLA 9

Uchida, Tomohisa, et al. “Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study.” Rheumatology, vol. 62, no. 10, 2023, pp. 3358–3365. https://doi.org/10.1093/rheumatology/kead079.

Chicago

Uchida, Tomohisa, Naoki Iwamoto, Shoichi Fukui, Shimpei Morimoto, Toshiyuki Aramaki, F. Shomura, Koichiro Aratake, Katsumi Eguchi, Yukitaka Ueki, and Atsushi Kawakami. 2023. “Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study.” Rheumatology 62 (10): 3358–3365. https://doi.org/10.1093/rheumatology/kead079.

Harvard

Uchida, T. et al. (2023) ‘Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study’, Rheumatology, 62(10), pp. 3358–3365. doi:10.1093/rheumatology/kead079.

IEEE

T. Uchida et al., “Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study,” Rheumatology, vol. 62, no. 10, pp. 3358–3365, 2023, doi: 10.1093/rheumatology/kead079.

BibTeX

@article{uchida2023comparison,
  title     = {{Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study}},
  author    = {Uchida, Tomohisa and Iwamoto, Naoki and Fukui, Shoichi and Morimoto, Shimpei and Aramaki, Toshiyuki and Shomura, F. and Aratake, Koichiro and Eguchi, Katsumi and Ueki, Yukitaka and Kawakami, Atsushi},
  journal   = {Rheumatology},
  year      = {2023},
  volume    = {62},
  number    = {10},
  pages     = {3358--3365},
  doi       = {10.1093/rheumatology/kead079},
  url       = {https://doi.org/10.1093/rheumatology/kead079}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202355
20241515
20251010
202699

Its field-weighted citation impact is 6.17: it has been cited 6.17 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • rheumatoid arthritis
  • tofacitinib
  • baricitinib
  • JAK inhibitors
  • TNF-alpha inhibitors
  • herpes zoster
  • infectious diseases
  • cancer risk

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Uchida, T., Iwamoto, N., Fukui, S., Morimoto, S., Aramaki, T., Shomura, F., Aratake, K., Eguchi, K., Ueki, Y., & Kawakami, A. (2023). Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study. Rheumatology, 62(10), 3358–3365. https://doi.org/10.1093/rheumatology/kead079

How many times has this paper been cited?

39 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Rheumatology: sign in and open the PDF from this page.

Who wrote this paper?

Tomohisa Uchida, Naoki Iwamoto, Shoichi Fukui, Shimpei Morimoto, Toshiyuki Aramaki, F. Shomura, Koichiro Aratake, Katsumi Eguchi, Yukitaka Ueki, Atsushi Kawakami.

What is the DOI of this paper?

10.1093/rheumatology/kead079, permanently at https://doi.org/10.1093/rheumatology/kead079. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.